Company Product Description Indication Status
Babylon Health, of London Artificial Intelligence (AI)-based symptom checker tool Uses causal machine learning Help doctors improve diagnosis Published research in Nature Communications showing that disentangling correlation from causation makes AI significantly more accurate in diagnosing patients based on symptoms; a pool of over 20 Babylon general practitioners (GPs) created 1,671 realistic written medical cases; a separate group of 44 Babylon GPs were then each given at least 50 written cases (the mean was 159) to assess; the doctors listed the illnesses they considered most likely; Babylon's AI took the same tests and used both an older algorithm based on correlations (created specifically for this research) and the newer, causal one; the doctors had a mean score of 71.40% (± 3.01%) and ranged from 50-90%; the older correlative algorithm performed on par with the average doctor, achieving 72.52% (± 2.97%); the new causal algorithm scored 77.26% (± 2.79%), which was higher than 32 of the doctors, equal to 1, and lower than 11
Beyond Air Inc., of Garden City, N.Y. Lungfit Nitric oxide (NO) generator and delivery system Treats pulmonary Mycobacterium abscessus disease Study evaluated the effect of inhaled NO therapy delivered via the Lungfit system, with inhaled NO doses titrated up to 240 ppm, as compassionate treatment in a 24-year-old, female cystic fibrosis patient with chronic and progressive pulmonary M. abscessus disease; the patient completed the first 3-week treatment course with no significant adverse effects noted; in general, the patient noted improved respiratory symptoms and quality of life and had small improvements in her lung function, 6-minute walk distance, and inflammatory markers but no significant change in tests and cultures for M. abscessus; given the overall tolerability of the first treatment, the patient requested to repeat the treatment, but dosing was stopped after day 8 due to adverse symptoms, which did not occur during administration of NO, and methemoglobin levels remained within safe thresholds at all times; in vitro susceptibility tests showed a dose-dependent NO effect on M. abscessus susceptibility and significant heterogeneity in response among M. abscessus clinical isolates; the patient's isolate was found to be the least susceptible strain in vitro; the research was published in Access Microbiology
Exthera Medical Corp., of Martinez, Calif. Seraph 100 Extracorporeal blood filter For the reduction of pathogens in blood Published case study in Critical Care Explorations in which the U.S. Department of Defense used the Seraph 100 to treat COVID-19; researchers at the Walter Reed Army Medical Center determined that the Seraph 100 may improve patient stability in COVID-19 cases requiring mechanical ventilation and vasopressor support; during and after the treatment with the Seraph 100, both patients experienced quantitative clinical improvement, and there were no device-related adverse events
Neurologica Corp., a Danvers, Mass-based subsidiary of Samsung Electronics Co. Ltd. GM85 mobile DR system with S-Vue Image Engine Mobile digital radiography (DR) system with a noise-reduction algorithm Imaging of patients in the neonatal intensive care unit A study in the American Journal of Roentgenology shows that low-dose protocols using the GM85 can deliver comparable image quality at up to a 36% lower dose; 40 neonatal patients underwent whole-body radiography with the GM85 protocol and a conventional protocol on another conventional mobile DR system; results showed that the low-dose protocols of both 80% and 64% equivalent dose "were statistically noninferior to the conventional protocol with respect to overall image quality," and the 80% dose had better overall image quality than the conventional protocol

Notes

For more information about individual companies and/or products, see Cortellis.


No Comments